Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Cervical Carcinoma: early-phase trial registry
2 of 10 indexed Recurrent Cervical Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Recurrent Cervical Carcinoma: 10 US clinical trials tracked, 2 recruiting.
Recurrent Cervical Carcinoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-cervical-carcinoma
OPEN 2 | RECR 20% | LATE 0 | EARLY 9 | RANK #1724 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)
Recurrent Cervical Carcinoma lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Cervical Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Cervical Carcinoma is recruiting below its size-band peers.
2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Cervical Carcinoma research.
National Cancer Institute (NCI) accounts for 4 of 10 trials (40%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Cervical Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 31 among the 10 trials that report a genuine target (sentinel values excluded). 10 of those (100%) plan for fewer than 100 participants.
-
Recurrent Cervical Carcinoma research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen
NCT06157151
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
NCT03968406
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Meghan Shea
NCT06238635
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT02257528
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Mayo Clinic
NCT04574635
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Gynecologic Oncology Group
NCT00309959
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT00057863
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Gynecologic Oncology Group
NCT01267253
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
NCT01266447
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT02921269
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Cervical Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Cervical Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Cervical Carcinoma page
10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Recurrent Cervical Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Cervical Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Cervical Carcinoma condition card totals 10 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.